Company: LBRX
Filing Date: 2025-11-12
Form Type: 8-K
Source: 0001193125-25-276070
Chunk: 0

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-11-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On November 12, 2025, LB Pharmaceuticals Inc (the “ Company”) announced that Kaya Pai Panandiker has been appointed to serve as the Company’s Chief Commercial Officer, effective as of November 10, 2025, and issued a press release.

Ms. Pai Panandiker, age 49, is joining the Company after most recently serving as the Chief Commercial Officer of Neumora Therapeutics, Inc. Previously, Ms. Pai Panandiker served as Head of Commercial at Cerevel Therapeutics Holdings, Inc. and General Manager, Neuroscience at H. Lundbeck A/S. Ms. Pai Panandiker received a B. A. from the University of Wisconsin-Madison and earned her Master’s degree in Public Policy from the University of Chicago.

As an inducement material to Ms. Pai Panandiker entering into employment with the Company, the Company intends to grant her an equity award outside of, but subject to the terms and conditions of, the Company’s 2025 Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference.